x

Cerca una sperimentazione clinica

* (*) campo obbligatorio

393 Risultato/i

Ordinato per

Sperimentazione in fase di reclutamento = Sperimentazione in fase di reclutamento
; Sperimentazione in corso = Sperimentazione in corso
; Finanziato da un ente associato a IRDiRC =

Sperimentazioni cliniche nazionali

AUSTRIA

WIEN
WIEN

SEAMLESS: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie

FRANCIA

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

GERMANIA

Baden-Württemberg
FREIBURG

Sperimentazione in fase di reclutamento
Sperimentazione in corso
CA209-9P9: Phase 1/2 Study on the Efficacy of Nivolumab in the Recurrence of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation

GERMANIA

Baden-Württemberg
HEIDELBERG

GERMANIA

Baden-Württemberg
HEIDELBERG

Sperimentazione in fase di reclutamento
Sperimentazione in corso
BLAST: A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

GERMANIA

Nordrhein-Westfalen
DÜSSELDORF

GERMANIA

Nordrhein-Westfalen
ESSEN

Sperimentazione in fase di reclutamento
Sperimentazione in corso
AML-BFM 2012: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

GERMANIA

Nordrhein-Westfalen
LEVERKUSEN

CLAVELA: A randomised phase III study of Elacytarabine versus investigator's choice in patients with late stage Acute Myeloid Leukaemia - DE - Completed
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie

GERMANIA

Sachsen
DRESDEN

GERMANIA

Sachsen
DRESDEN

Sperimentazione in fase di reclutamento
Sperimentazione in corso
TUD-BRIDGE-046: Clofarabine salvage therapy in patients with relapsed or refractory Acute Myeloid Leukemia (Phase II Study)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANIA

Sachsen
DRESDEN

Sperimentazione in fase di reclutamento
Sperimentazione in corso
DELTA: A randomized placebo-controlled phase 2 study of decitabine/azacitidine with or without eltrombopag in AML patients = / > 65 years of age not eligible for intensive chemotherapy - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANIA

Sachsen
DRESDEN

Sperimentazione in fase di reclutamento
Sperimentazione in corso
ETAL3-ASAP: Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients with AML (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANIA

Sachsen
DRESDEN

SAMBA: Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANIA

Sachsen
DRESDEN

Sperimentazione in corso
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden

PAESI BASSI

Zuid-Holland
LEIDEN

POLONIA

Wroclaw
WROCLAW

CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - PL
Uniwersytet Medyczny im. Piastow Slaskich - Wroclaw Medical University
Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku

REGNO UNITO; GRAN BRETAGNA

Greater London
LONDON

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

REGNO UNITO; GRAN BRETAGNA

Nottinghamshire
NOTTINGHAM

REGNO UNITO; GRAN BRETAGNA

South Glamorgan
CARDIFF

AML 14: A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over (phase III) - UK
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REGNO UNITO; GRAN BRETAGNA

South Glamorgan
CARDIFF

SPAGNA

Comunidad Valenciana
VALENCIA

SPAGNA

Comunidad Valenciana
VALENCIA

SPAGNA

Comunidad Valenciana
VALENCIA

SPAGNA

Navarra
PAMPLONA

CLAVELA: A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia - ES (completed)
Complejo Hospitalario de Navarra - Hospital Virgen del Camino
Servicio de Hematología y Hemoterapia

DANIMARCA

Jylland
AARHUS

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (Phase III)
Aarhus Universitetshospital - Skejby
Department of Pediatrics

FRANCIA

AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR

FRANCIA

AUVERGNE-RHONE-ALPES
LYON

CLARA-DNX : A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
GH Est des HCL - Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)
Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse

FRANCIA

ILE-DE-FRANCE
LE CHESNAY

FRANCIA

ILE-DE-FRANCE
PARIS

Sperimentazione in corso
TBF-Cord : Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (Phase II)
CHU Paris Est - Hôpital Saint-Antoine
Service d'hématologie clinique et thérapie cellulaire

FRANCIA

ILE-DE-FRANCE
PARIS

Haploidentical NK-cell Infusion in Bad Prognosis AML Patients: Evaluation of Feasibility and Antitumoral Effect (Phase I-II) - FR
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Service d'Hématologie clinique

FRANCIA

ILE-DE-FRANCE
PARIS

Sperimentazione in fase di reclutamento
Sperimentazione in corso
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q (GFM-Aza-Rev-09)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Groupe Francophone des Myélodysplasies (GFM)

FRANCIA

ILE-DE-FRANCE
PARIS

5-Azacitidine, Valproic Acid and ATRA in AML and High Risk MDS (Phase II) - Terminated -
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service : Centre des Maladies du Sang

FRANCIA

ILE-DE-FRANCE
PARIS

Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (Phase III)
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Service d'Hématologie seniors

FRANCIA

ILE-DE-FRANCE
PARIS

FRANCIA

OCCITANIE
MONTPELLIER

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Acute Myeloid Leukemia - Terminated -
CLCC Institut Paoli Calmettes
Unité d'Evaluation Thérapeutique en Onco-Hématologie (ETHO)

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

FRANCIA

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

GERMANIA

Baden-Württemberg
FREIBURG

GERMANIA

Baden-Württemberg
HEIDELBERG

GERMANIA

Baden-Württemberg
HEIDELBERG

Phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with Acute Myeloid Leukemia (AML) with FLT3-ITD activating mutations - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

GERMANIA

Baden-Württemberg
TÜBINGEN

Sperimentazione in fase di reclutamento
Sperimentazione in corso
CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin II - Onkologie, Hämatologie, Klinische Immunologie, Rheumatologie und Pulmologie

GERMANIA

Bayern
MÜNCHEN

Sperimentazione in fase di reclutamento
Sperimentazione in corso
A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy -DE-
Klinikum rechts der Isar der Technischen Universität München
Klinik und Poliklinik für Innere Medizin III

GERMANIA

Bayern
MÜNCHEN

GERMANIA

Niedersachsen
HANNOVER

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
KPOH Geschäftsführung Hannover
Kompetenznetz Pädiatrische Onkologie und Hämatologie

GERMANIA

Nordrhein-Westfalen
ESSEN

AML-BFM 2004 : Multicenter therapy-optimization trial for the treatment of Acute Myeloid Leukemias in children and adolescents - DE
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

GERMANIA

Nordrhein-Westfalen
LEVERKUSEN

CP4055-205: A Phase II Study of Elacytarabine (CP-4055) plus Idarubicin as second course remission-induction therapy in patients with Acute Myeloid Leukaemia (AML) - DE
Klinikum Leverkusen
Medizinische Klinik 3 - Onkologie, Hämatologie, Palliativmedizin, Spezielle Schmerztherapie

GERMANIA

Sachsen
DRESDEN

Gentuzumab ozogamicin before allogeneic stem cell transplantation in patients with relapsed CD33+ Acute Myeloid Leukemia (Phase I-II) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANIA

Sachsen
DRESDEN

TUD-LENAMA-022: Lenalidomide maintenance therapy in patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukaemia (AML) - Phase II study - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANIA

Sachsen
DRESDEN

TUD-RELAZA-008: Treatment of the haematological relapse in patients with AML and MDS following allogenic Stem Cell Transplantation with 5-Azacitidine (Vidaza®) (Phase III) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation

GERMANIA

Thüringen
JENA

Phase II study of Cladribine, high-dose Cytarabine and Idarubicin in patients with relapsed acute myeloid leukemia - DE
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

GERMANIA

Thüringen
JENA

Sperimentazione in corso
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Universitätsklinikum Jena
Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

ITALIA

FRIULI VENEZIA GIULIA
UDINE

Sperimentazione in fase di reclutamento
Sperimentazione in corso
Terapia in pazienti al di sotto dei 66 anni con Leucemia Mieloide Acuta
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Clinica Ematologica

ITALIA

LAZIO
ROMA

Sperimentazione in fase di reclutamento
Sperimentazione in corso
Protocollo per la leucemia acuta mieloide in età pediatrica
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Onco-Ematologia

ITALIA

LAZIO
ROMA

Sperimentazione in corso
Clofarabine in combinazione con AraC e iderubicina in pazienti di età tra i 20 e 60 anni con precedenti non trattati e rischio per leucemia acuta mielogenoide (AML)
Sapienza Università di Roma - Dipartimento di Neurologia e Psichiatria
Dipartimento di Biotecnologie Cellulari ed Ematologia

PAESI BASSI

Gelderland
NIJMEGEN

REGNO UNITO; GRAN BRETAGNA

Greater London
LONDON

A Phase I Study of the Human Pharmacokinetics and Cardiac Safety of Elacytarabine - GB
St Bartholomew's Hospital, Barts and The London NHS Trust
Department of Medical Oncology

REGNO UNITO; GRAN BRETAGNA

South Glamorgan
CARDIFF

Sperimentazione in corso
AML 16: A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (PhaseII/III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REGNO UNITO; GRAN BRETAGNA

South Glamorgan
CARDIFF

Sperimentazione in fase di reclutamento
Sperimentazione in corso
AML 17: Randomised, controlled, open label, multi-arm trial looking at treatment for acute promyelocytic leukaemia (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REGNO UNITO; GRAN BRETAGNA

South Glamorgan
CARDIFF

AML 15: Medical research council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15 (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REGNO UNITO; GRAN BRETAGNA

South Glamorgan
CARDIFF

AML-HR: Protocol for patients with high risk (resistant, refractory, relapsed or adverse cytogenetic) AML (Phase III)
Cardiff University School of Medicine
Department of Medical Genetics, Haematology & Pathology

REGNO UNITO; GRAN BRETAGNA

West Yorkshire
LEEDS

SPAGNA

Cataluña
BADALONA

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica

SPAGNA

Comunidad Valenciana
VALENCIA

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia

SPAGNA

Madrid
MADRID

SPAGNA

Madrid
MADRID

APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) (Phase IV) (completed)
Hospital Universitario 12 de Octubre
Servicio de Hematología y Hemoterapia

SPAGNA

Madrid
MADRID

PETHEMA-LAM99: Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years (Phase IV) (terminated)
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia

SPAGNA

Navarra
PAMPLONA

BELGIO

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Sperimentazione in corso
STEP: Sorafenib Long Term Extension Program - BE
Cliniques Universitaires UCL Saint-Luc
Pneumologie_Oncologie thoracique

Sperimentazioni cliniche internazionali

GERMANIA

Berlin
ADDRESS: NOT PROVIDED - DE

REGNO UNITO; GRAN BRETAGNA

Greater Manchester
ADDRESS: NOT PROVIDED - UK

STATI UNITI

New Jersey
RARITAN